ArticleCureus2026
Validation of the MTXPK Tool in Predicting Glucarpidase Utilization Among Patients With Delayed Methotrexate Clearance: A Retrospective Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Glucarpidase, a recombinant bacterial enzyme, can treat patients with methotrexate (MTX) toxicity. Identifying appropriate administration of glucarpidase can be challenging. MTXPK.org, a web-based clinical decision tool, maps projected MTX clearance for individual patients based on demographics and serum MTX levels to identify patients at the highest risk for toxicity who might benefit from glucarpidase administration. Here, we report our single institution experience with the predictive value of the MTXPK web tool in guiding glucarpidase administration. Methods Retrospective data collection conducted from 2000 through 2023 of patients admitted for high-dose methotrexate (HDMTX) who received glucarpidase therapy. Data required for utilization of the MTXPK tool were collected (age, sex, race, height, weight, MTX dose, creatinine, serum MTX, albumin, and the presence of pleural effusion). Data was input into the MTXPK tool to plot a curve of MTX clearance rate for each patient compared to the population predicted curve. Patient MTX clearance rates that fell below the predicted population rates were candidates for glucarpidase. Results Thirteen patients were included for review, with ages ranging from four months to 72 years, with an average of 47.7 years. Nine patients (69%) were male, and four (31%) were female. Twelve were Caucasian patients (92.3%), and one was a Black patient (7.7%). Average height and weight were 66.6 inches and 83.6 kg, respectively, with an average body surface area (BSA) of 1.99 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.